drugset / Trial / NCT06475235
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: * Pembrolizumab (a type of monoclonal antibody) * Methotrexate (a type of anti-metabolite) * Temozolomide (a type of alkylating agent) * Rituximab (a type of antibody)
Timeline
- Start
- 2024-10-18
- Primary completion
- 2026-12-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Temozolomide | Small molecule | — | Oral |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |